Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
28 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Etubics Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Etubics Corporation - Product Pipeline Review - 2014', provides an overview of the Etubics Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Etubics Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Etubics Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Etubics Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Etubics Corporation's pipeline products Reasons to buy - Evaluate Etubics Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Etubics Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Etubics Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Etubics Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Etubics Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Etubics Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Etubics Corporation Snapshot 4 Etubics Corporation Overview 4 Key Information 4 Key Facts 4 Etubics Corporation - Research and Development Overview 5 Key Therapeutic Areas 5 Etubics Corporation - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Etubics Corporation - Pipeline Products Glance 9 Etubics Corporation - Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Phase I Products/Combination Treatment Modalities 10 Etubics Corporation - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Etubics Corporation - Drug Profiles 12 ETBX-011 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 ETBX-021 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Recombinant Vector Vaccine for HIV 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Recombinant Vector Vaccine for Influenza 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Recombinant Vector Vaccine for Malaria 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Vaccine for HPV-Head and Neck Cancer 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Etubics Corporation - Pipeline Analysis 20 Etubics Corporation - Pipeline Products by Target 20 Etubics Corporation - Pipeline Products by Route of Administration 21 Etubics Corporation - Pipeline Products by Molecule Type 22 Etubics Corporation - Recent Pipeline Updates 23 Etubics Corporation - Dormant Projects 25 Etubics Corporation - Locations And Subsidiaries 26 Head Office 26 Appendix 27 Methodology 27 Coverage 27 Secondary Research 27 Primary Research 27 Expert Panel Validation 27 Contact Us 28 Disclaimer 28
List of Tables Etubics Corporation, Key Information 4 Etubics Corporation, Key Facts 4 Etubics Corporation - Pipeline by Indication, 2014 6 Etubics Corporation - Pipeline by Stage of Development, 2014 7 Etubics Corporation - Monotherapy Products in Pipeline, 2014 8 Etubics Corporation - Phase II, 2014 9 Etubics Corporation - Phase I, 2014 10 Etubics Corporation - Preclinical, 2014 11 Etubics Corporation - Pipeline by Target, 2014 20 Etubics Corporation - Pipeline by Route of Administration, 2014 21 Etubics Corporation - Pipeline by Molecule Type, 2014 22 Etubics Corporation - Recent Pipeline Updates, 2014 23 Etubics Corporation - Dormant Developmental Projects,2014 25
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.